SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines ...
Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment There were no meaningful changes ...
In a recent study published in PLoS ONE, researchers assessed the binding of Galanthus nivalis agglutinin to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Study: Removal of ...
OncoGenex Pharmaceuticals, Inc. OGXI announced the FDA’s agreement to the proposed amendment to its protocol and statistical analysis plan for the ongoing phase III study, AFFINITY, on custirsen for ...
A team of scientists from China has recently deciphered the structural basis of comparatively higher binding affinity of two Omicron sub-variants, namely B.1.1 and B.2, for human ...
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback